Host Genotype Links to Salivary and Gut Microbiota by Periodontal Status

Limited evidence describing how host genetic variants affect the composition of the microbiota is currently available. The aim of this study was to assess the associations between a set of candidate host genetic variants and microbial composition in both saliva and gut in the TwinsUK registry. A total of 1,746 participants were included in this study and provided stool samples. A subset of 1,018 participants also provided self-reported periodontal data, and 396 of those participants provided a saliva sample. Host DNA was extracted from whole-blood samples and processed for Infinium Global screening array, focusing on 37 selected single-nucleotide polymorphisms (SNPs) previously associated with periodontitis. The gut and salivary microbiota of participants were profiled using 16S ribosomal RNA amplicon sequencing. Associations between genotype on the selected SNPs and microbial outcomes, including α diversity, β diversity, and amplicon sequence variants (ASVs), were investigated in a multivariate mixed model. Self-reported periodontal status was also compared with microbial outcomes. Downstream analyses in gut microbiota and salivary microbiota were carried out separately. IL10 rs6667202 and VDR 2228570 SNPs were associated with salivary α diversity, and SNPs in IL10, HSA21, UHRF2, and Fc-γR genes were associated with dissimilarity matrix generated from salivary β diversity. The SNP that was associated with the greatest number of salivary ASVs was VDR 2228570 followed by IL10 rs6667202, and that of gut ASVs was NPY rs2521364. There were 77 salivary ASVs and 39 gut ASVs differentially abundant in self-reported periodontal disease versus periodontal health. The dissimilarity between saliva and gut microbiota within individuals appeared significantly greater in self-reported periodontal cases compared to periodontal health. IL10 and VDR gene variants may affect salivary microbiota composition. Periodontal status may drive variations in the salivary microbiota and possibly, to a lesser extent, in the gut microbiota.

Pre-microRNAs single nucleotide variants (rs3746444 A > G and rs2910164 C > G) increase the risk of ischemic stroke in the Egyptian population: a case–control study

Background

Ischemic stroke (IS) is the most leading cause of morbidity and mortality worldwide. Micro RNA (miRNA) genetic variants have been identified as a part of IS non-modifiable risk markers. This study aims to identify the possible association of rs2910164 C > G of pre-miRNA-146a and rs3746444 A > G of pre-miRNA-499 with increased IS risk. C-reactive protein (CRP) was studied as one of the mediators of the genetic disturbance in IS. The study included 100 patients with atherosclerotic IS and 100 age and sex matched healthy controls with more than one risk factor for IS. Variants were evaluated by the real-time polymerase chain reaction technique using TaqMan probes. CRP levels were assayed by immunoturbidimetry method on COBAS analyzer.

Results

Regarding rs3746444 A > G, the G allele, and its containing genotypes (GG and GG + AG) were associated with high IS incidence. Increased CRP levels were found to induce IS by GG and GG + AG genotypes, with a cut value of 7.5 mg/ L in differentiation between AA genotype and GG + AG genotypes. Combining the G allele of rs3746444 A > G with either G or C allele of rs2910164 C > G had enhanced the risk. For rs2910164 C > G, the G allele, and the combined GG + GC genotypes were associated with IS risk elevation with no correlation to CRP levels.

Conclusion

The G involving genetic variants of rs3746444 A > G and rs2910164 C > G were associated with an enhanced IS risk. CRP showed higher levels in GG and AG genotypes of rs3746444 with no relation to rs2910164 genotypes.

Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs

Mixed Cryoglobulinemic Vasculitis (MCV) is a prominent extra-hepatic manifestation of Hepatitis C virus (HCV) infection. HCV has been reported to cause B-cell disorders and genomic instability. Here, we investigated B-cell activation and genome stability in HCV-MCV patients receiving the direct antiviral agent, Sofosbuvir, at multiple centers in Egypt. Clinical manifestations in HCV-MCV patients were improved at the end of treatment (EOT), such as purpura (100%), articular manifestations (75%) and neuropathy (68%). Eighteen patients (56%) showed vasculitis relapse after EOT. BAFF and APRIL were higher at EOT and continued to increase one year following treatment onset. Chromosomal breaks were elevated at EOT compared to baseline levels and were sustained at 3 and 6 months post treatment. We report increased expression of DNA genome stability transcripts such as topoisomerase 1 and TDP1 in HCV-MCV patients after treatment, which continued to increase at 12 months from treatment onset. This data suggest that B-cell activation and DNA damage are important determinants of HCV-MCV treatment outcomes.